These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15153802)

  • 1. Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?
    Leach F
    Cancer Biol Ther; 2004 Jun; 3(6):559-60. PubMed ID: 15153802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).
    Mhaka A; Gady AM; Rosen DM; Lo KM; Gillies SD; Denmeade SR
    Cancer Biol Ther; 2004 Jun; 3(6):551-8. PubMed ID: 15044850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
    Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
    Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in prostate-specific membrane antigen-mediated antitumor drugs].
    Lü QZ; Yang JC; Wang YJ
    Yao Xue Xue Bao; 2016 Feb; 51(2):234-40. PubMed ID: 29856576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
    Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
    Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
    Aggarwal S; Singh P; Topaloglu O; Isaacs JT; Denmeade SR
    Cancer Res; 2006 Sep; 66(18):9171-7. PubMed ID: 16982760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
    Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
    J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.
    Xu B; Zhou F; Yan MM; Cai DS; Guo WB; Yang YQ; Jia XH; Zhang WX; Li T; Ma T; Wang PL; Lei HM
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.
    Kasten BB; Liu T; Nedrow-Byers JR; Benny PD; Berkman CE
    Bioorg Med Chem Lett; 2013 Jan; 23(2):565-8. PubMed ID: 23232055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
    Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
    Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus.
    Warren P; Li L; Song W; Holle E; Wei Y; Wagner T; Yu X
    Cancer Res; 2001 Sep; 61(18):6783-7. PubMed ID: 11559551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer.
    Dhull A; Wei J; Pulukuri AJ; Rani A; Sharma R; Mesbahi N; Yoon H; Savoy EA; Xaivong Vi S; Goody KJ; Berkman CE; Wu BJ; Sharma A
    Nanoscale; 2024 Mar; 16(11):5634-5652. PubMed ID: 38440933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.